Short answer
Nkarta, Inc. (NKTX) filed its Q2 2026 10-Q quarterly report on Aug 10, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$40M
- −75.7% YoY · −45.0% QoQ
- EPS (diluted)
- −$0.55
- −77.4% YoY · −48.6% QoQ
Source: XBRL data from the Nkarta, Inc. (NKTX) Q2 2026 10-Q on SEC EDGAR. USD.
Nkarta, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- No product revenue; no products approved for sale
- Significant losses since inception; continued losses expected for the foreseeable future
- Additional capital required, with potential dilution or operational restrictions
- Key near-term dependency: NKX019 clinical success and regulatory approval
- Major headwinds: clinical uncertainty, enrollment delays, manufacturing complexity, and competition
Risk Factors
- Newly triggered impairment risk: June 2026 manufacturing optimization and facility sublease rendered equipment unused, causing long-lived-asset impairment charges
- Most materially updated financial risk: net losses reached $68.2 million for six months ended June 30, 2026, with accumulated deficit of $716.5 million
- Regulatory risk: novel CAR NK autoimmune therapies lack FDA-approved precedents, potentially extending review and delaying commercialization
- Operational risk: halted enrollment in hematologic-malignancy trials after deprioritizing NKX019 and NKX101 programs
- Financing risk: $243.2 million in cash, restricted cash, equivalents and investments as of June 30, 2026, but pivotal trials require additional capital
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Nkarta, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.